Emmaus Life Sciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Revenues, Net - Summarizes Revenues from Each of our Customers Accounted for 10% or More of Net Revenues (Details)

Revenues, Net - Summarizes Revenues from Each of our Customers Accounted for 10% or More of Net Revenues (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Customer A [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	13.00%	22.00%
Customer B [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	23.00%	23.00%
Customer C [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	14.00%	8.00%
Customer D [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	12.00%	18.00%
Total Customers [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	62.00%	71.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References + Details